Yıl: 2019 Cilt: 24 Sayı: 3 Sayfa Aralığı: 361 - 370 Metin Dili: İngilizce DOI: 10.5505/ejm.2019.21447 İndeks Tarihi: 02-03-2020

Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology

Öz:
Endometrial cancer is the sixth most common neoplasm in women worldwide, with a rising incidence largely attributed tothe ongoing obesity epidemic. TNF-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL receptors have been testedfor their predictive, diagnostic, and prognostic values in various cancers, as well as for possible use in combinationtherapies. The roles of TRAIL and its receptors in endometrial tissue biology has not yet been cleared, and the potential ofthese molecules as biomarkers in endometrial cancer is yet to be defined. We investigated the expression profiles of TRAILand its transmembrane receptors during endometrial carcinogenesis to evaluate their potential as prognostic markers.Paraffin-embedded normal endometrium (n=18), endometrial hyperplasia (n=27), and endometrioid endometrialadenocarcinoma tissues (n=100) were analysed for TRAIL and receptor expression profiles via immunohistochemicalstaining. Apoptotic indexes in the corresponding tissues were defined by TUNEL assay.Endometrial carcinoma displayed decreased TRAIL and DR4 expressions compared to the normal endometrium, whileincreased DR5 and decoy receptor (DcR1 and DcR2) expressions were evident. The complex atypical hyperplasia displayedthe most similar expression profiles to the endometrial carcinoma, in accordance with the greatest risk of progression toendometrial carcinoma attributed to this tissue type. TRAIL/TRAIL receptor expression levels did not correlate with theprognostic factors of tumor stage or grade, or depth of myometrial invasion.Overall, distinct profiles of TRAIL and its receptor expressions were evident in progression from normal endometrium tohyperplasia and cancer, which may indicate significance of TRAIL signaling in the course of endometrial carcinomadevelopment.
Anahtar Kelime:

Konular: Diş Hekimliği Toksikoloji Farmakoloji ve Eczacılık
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
1
1
1
  • 1. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014; 15: e268-278.
  • 2. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomarkers Prev 2017; 26: 444-457.
  • 3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7- 30.
  • 4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.
  • 5. Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Res 2005; 322: 53-61.
  • 6. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16: 8-13.
  • 7. Reed SD, Newton KM, Clinton WL et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009; 200: 678.e1-6.
  • 8. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004; 35: 649-662.
  • 9. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001; 6: 191-197.
  • 10. Harith HH, Morris MJ, Kavurma MM. On the TRAIL of obesity and diabetes. Trends Endocrinol Metab 2013; 24: 578-587.
  • 11. Secchiero P, Gonelli A, Carnevale E et al. Evidence for a proangiogenic activity of TNFrelated apoptosis-inducing ligand. Neoplasia 2004; 6: 364-373.
  • 12. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559-563.
  • 13. Wiley SR, Schooley K, Smolak PJ et al., Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
  • 14. Pitti RM, Marsters SA, Ruppert S et al., Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690.
  • 15. Sanlioglu AD, Dirice E, Elpek O et al. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas 2009; 38: 154-160.
  • 16. Sanlioglu AD, Dirice E, Elpek O et al. High levels of endogenous tumor necrosis factorrelated apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas 2008; 36: 385-393.
  • 17. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS, Sanlioglu S. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 2008; 26: 158- 165.
  • 18. Sanlioglu AD, Korcum AF, Pestereli E et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 716-723.
  • 19. Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
  • 20. Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factorrelated apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
  • 21. Koschny R, Walczak H, Ganten TM. The promise of TRAIL--potential and risks of a novel anticancer therapy. J Mol Med (Berl) 2007; 85: 923-935.
  • 22. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782-798.
  • 23. Aydin C, Sanlioglu AD, Bisgin A et al. NFkappaB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. BMC Cancer 2010 27; 10: 584.
  • 24. Terzioglu E, Bisgin A, Sanlioglu AD et al. Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 783-789.
  • 25. Dirice E, Sanlioglu AD, Kahraman S et al. Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocininduced diabetic rats. Hum Gene Ther 2009; 20: 1177-1189.
  • 26. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201: 331-340.
  • 27. Secchiero P, Zerbinati C, Rimondi E et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004; 61: 1965-1974.
  • 28. Janssen EM, Droin NM, Lemmens EE et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activationinduced cell death. Nature 2005; 434: 88-93.
  • 29. Ganten TM, Sykora J, Koschny R et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) 2009; 87: 995- 1007.
  • 30. Sträter J, Hinz U, Walczak H et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002; 8: 3734-3740.
  • 31. Maduro JH, Noordhuis MG, ten Hoor KA et al. The prognostic value of TRAIL and its death receptors in cervical cancer. Int J Radiat Oncol Biol Phys 2009; 75: 203-211.
  • 32. Lancaster JM, Sayer R, Blanchette C et al. High expression of tumor necrosis factorrelated apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 2003; 9: 762-766.
  • 33. Spierings DC, de Vries EG, Timens W et al. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003; 9: 3397- 3405.
  • 34. Binder PS, Mutch DG. Update on prognostic markers for endometrial cancer. Womens Health (Lond) 2014; 10: 277-288.
  • 35. Appel ML, Edelweiss MI, Fleck J et al. P53 and BCL-2 as prognostic markers in endometrial carcinoma. Pathol Oncol Res 2008; 14: 23-30.
  • 36. Dolcet X, Llobet D, Pallares J et al. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005; 85: 885-894.
  • 37. Llobet D, Eritja N, Encinas M et al. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 2008; 27: 2513- 2524.
  • 38. Llobet D, Pallares J, Yeramian A et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 2009; 62: 777-785.
  • 39. Pallares J, Martínez-Guitarte JL, Dolcet X et al. Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol 2005; 24: 247-253.
  • 40. Dolcet X, Llobet D, Pallares J et al., NF-kB in development and progression of human cancer. Virchows Arch 2005; 446: 475-482.
  • 41. Pallares J, Llobet D, Santacana M et al. CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. Am J Pathol 2009; 174: 287-296.
  • 42. Cullen SP, Martin SJ. Fas and TRAIL 'death receptors' as initiators of inflammation: Implications for cancer. Semin Cell Dev Biol 2015; 39: 26-34.
  • 43. Sanlioglu AD, Koksal IT, Karacay B et al. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAILinduced apoptosis. Cancer Gene Ther 2006; 13: 21-31.
  • 44. Sanlioglu AD, Dirice E, Aydin C et al. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005; 5: 54.
  • 45. Zhang XD, Franco A, Myers K et al. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747-2753.
  • 46. Nimmanapalli R, Perkins CL, Orlando M et al. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001; 61: 759-763.
  • 47. Sanlioglu AD, Karacay B, Koksal IT, Griffith TS, Sanlioglu S. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther 2007; 14: 976-984.
  • 48. Aydin C, Sanlioglu AD, Karacay B et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factorrelated apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther 2007; 18: 39-50.
  • 49. Pan G, Ni J, Wei YF et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815- 818.
  • 50. Zhang XD, Franco AV, Nguyen T et al. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000; 164: 3961- 3970.
  • 51. Tarragona J, Llecha N, Santacana M et al. DcR1 expression in endometrial carcinomas. Virchows Arch 2010; 456: 39-44.
  • 52. Bisgin A, Terzioglu E, Aydin C et al. TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskelet Disord 2010; 11: 192.
  • 53. Gottwald L, Piekarski J, Kubiak R et al. Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study. Arch Gynecol Obstet 2013; 288: 889-899.
  • 54. Gottwald L, Szwalski J, Piekarski J et al. Membrane expression of the death ligand trail receptors DR4 and DR5 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer. J Obstet Gynaecol 2013; 33: 512-518.
  • 55. Gottwald L, Pasz-Walczak G, Piekarski J et al. Membrane expression of trail receptors DcR1 and DcR2 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer. J Obstet Gynaecol 2014; 34: 346-349.
APA AYDIN ACAR Ç, Bisgin A, ŞANLIOĞLU A, PEŞTERELİ H, ERDOĞAN G, Ozbudak I, ŞİMŞEK T, ŞANLIOĞLU S (2019). Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. , 361 - 370. 10.5505/ejm.2019.21447
Chicago AYDIN ACAR ÇİĞDEM,Bisgin Atil,ŞANLIOĞLU AHTER DİLŞAD,PEŞTERELİ Hadice Elif,ERDOĞAN Gülgün,Ozbudak Irem Hicran,ŞİMŞEK Tayup,ŞANLIOĞLU Salih Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. (2019): 361 - 370. 10.5505/ejm.2019.21447
MLA AYDIN ACAR ÇİĞDEM,Bisgin Atil,ŞANLIOĞLU AHTER DİLŞAD,PEŞTERELİ Hadice Elif,ERDOĞAN Gülgün,Ozbudak Irem Hicran,ŞİMŞEK Tayup,ŞANLIOĞLU Salih Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. , 2019, ss.361 - 370. 10.5505/ejm.2019.21447
AMA AYDIN ACAR Ç,Bisgin A,ŞANLIOĞLU A,PEŞTERELİ H,ERDOĞAN G,Ozbudak I,ŞİMŞEK T,ŞANLIOĞLU S Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. . 2019; 361 - 370. 10.5505/ejm.2019.21447
Vancouver AYDIN ACAR Ç,Bisgin A,ŞANLIOĞLU A,PEŞTERELİ H,ERDOĞAN G,Ozbudak I,ŞİMŞEK T,ŞANLIOĞLU S Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. . 2019; 361 - 370. 10.5505/ejm.2019.21447
IEEE AYDIN ACAR Ç,Bisgin A,ŞANLIOĞLU A,PEŞTERELİ H,ERDOĞAN G,Ozbudak I,ŞİMŞEK T,ŞANLIOĞLU S "Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology." , ss.361 - 370, 2019. 10.5505/ejm.2019.21447
ISNAD AYDIN ACAR, ÇİĞDEM vd. "Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology". (2019), 361-370. https://doi.org/10.5505/ejm.2019.21447
APA AYDIN ACAR Ç, Bisgin A, ŞANLIOĞLU A, PEŞTERELİ H, ERDOĞAN G, Ozbudak I, ŞİMŞEK T, ŞANLIOĞLU S (2019). Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. Eastern Journal of Medicine, 24(3), 361 - 370. 10.5505/ejm.2019.21447
Chicago AYDIN ACAR ÇİĞDEM,Bisgin Atil,ŞANLIOĞLU AHTER DİLŞAD,PEŞTERELİ Hadice Elif,ERDOĞAN Gülgün,Ozbudak Irem Hicran,ŞİMŞEK Tayup,ŞANLIOĞLU Salih Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. Eastern Journal of Medicine 24, no.3 (2019): 361 - 370. 10.5505/ejm.2019.21447
MLA AYDIN ACAR ÇİĞDEM,Bisgin Atil,ŞANLIOĞLU AHTER DİLŞAD,PEŞTERELİ Hadice Elif,ERDOĞAN Gülgün,Ozbudak Irem Hicran,ŞİMŞEK Tayup,ŞANLIOĞLU Salih Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. Eastern Journal of Medicine, vol.24, no.3, 2019, ss.361 - 370. 10.5505/ejm.2019.21447
AMA AYDIN ACAR Ç,Bisgin A,ŞANLIOĞLU A,PEŞTERELİ H,ERDOĞAN G,Ozbudak I,ŞİMŞEK T,ŞANLIOĞLU S Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. Eastern Journal of Medicine. 2019; 24(3): 361 - 370. 10.5505/ejm.2019.21447
Vancouver AYDIN ACAR Ç,Bisgin A,ŞANLIOĞLU A,PEŞTERELİ H,ERDOĞAN G,Ozbudak I,ŞİMŞEK T,ŞANLIOĞLU S Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology. Eastern Journal of Medicine. 2019; 24(3): 361 - 370. 10.5505/ejm.2019.21447
IEEE AYDIN ACAR Ç,Bisgin A,ŞANLIOĞLU A,PEŞTERELİ H,ERDOĞAN G,Ozbudak I,ŞİMŞEK T,ŞANLIOĞLU S "Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology." Eastern Journal of Medicine, 24, ss.361 - 370, 2019. 10.5505/ejm.2019.21447
ISNAD AYDIN ACAR, ÇİĞDEM vd. "Expression Profiles of TRAIL and Its Receptors in Normal, Hyperplastic, and Malignant Endometrial Tissues: Hints on Endometrial Cancer Biology". Eastern Journal of Medicine 24/3 (2019), 361-370. https://doi.org/10.5505/ejm.2019.21447